Comparative Meta-Analysis of Survival, Risk, and Treatment Efficacy in Immunotherapy for Metastatic Melanoma Using Random-, Fixed-, and Mixed-Effects Models
Journal of Clinical Medicine · 15.07.2025 · 14 (14) · 5017
DOI: 10.3390/jcm14145017 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 15.07.2025. Verfasst von Jelena Ivetić und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Technical Sciences, University of Novi Sad, 21000 Novi Sad, Serbia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Fund of the Republic of Serbia, Ministry of Science, Technological Development and Innovation, Faculty of Technical Sciences, University of Novi Sad.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) have reshaped the treatment landscape of metastatic melanoma. While combination regimens often demonstrate improved response and survival compared to monotherapy, they are also associated with a higher incidence of immune-related adverse events (irAEs). Understanding the balance between benefit and risk is essential for making informed treatment decisions, especially given the variability in reported outcomes across clinical trials.
Methods
We conducted a systematic review and meta-analysis of 14 clinical trials (comprising 22 treatment arms and >5000 patients) comparing ICI monotherapy (nivolumab, ipilimumab, or pembrolizumab) and combination therapy (nivolumab + ipilimumab) in advanced melanoma. Treatment-related outcomes were synthesized using fixed-effects, random-effects, or generalized linear mixed models (GLMMs), depending on study variability. Survival data were extracted from published Kaplan–Meier curves and analyzed using longitudinal GLMMs to capture trends over time.
Results
Compared to monotherapy, combination immunotherapy achieved higher clinical benefit, with an overall response of 52.2% (vs. 31.6%), a five-year overall survival of 55.7% (vs. 34.3%), and a five-year progression-free survival of 39.0% (vs. 17.2%). However, this benefit came with a higher risk of toxicity: immune-related adverse events occurred in 93.2% of patients receiving combination therapy versus in 81.9% receiving monotherapy. Differences were consistent across all individual severe toxicities.
Conclusions
Combination immunotherapy offers greater long-term clinical benefit than monotherapy in metastatic melanoma but at the cost of increased toxicity. By applying models adapted to study variability, we provide more reliable estimates of treatment efficacy and risk. GLMMs provide the most robust estimates and enable the modeling of survival dynamics over time. These findings support evidence-based decision-making and highlight the value of model-informed meta-analysis in oncology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Technical Sciences, University of Novi Sad, 21000 Novi Sad, Serbia.
ORCID-Profile: Jelena Ivetić, Jovana Dedeić
Förderung
- Science Fund of the Republic of Serbia
- Ministry of Science, Technological Development and Innovation
- Faculty of Technical Sciences, University of Novi Sad
Zitieren
APA
Ivetić, J., Dedeić, J., Milićević, S., Vidojević, K., & Delić, M. (2025). Comparative Meta-Analysis of Survival, Risk, and Treatment Efficacy in Immunotherapy for Metastatic Melanoma Using Random-, Fixed-, and Mixed-Effects Models. Journal of Clinical Medicine, 14(14), 5017. https://doi.org/10.3390/jcm14145017
Vancouver
Ivetić J, Dedeić J, Milićević S, Vidojević K, Delić M. Comparative Meta-Analysis of Survival, Risk, and Treatment Efficacy in Immunotherapy for Metastatic Melanoma Using Random-, Fixed-, and Mixed-Effects Models. Journal of Clinical Medicine. 2025;14(14):5017. doi:10.3390/jcm14145017
BibTeX
@article{Iveti2025,
author = {Ivetić, Jelena and Dedeić, Jovana and Milićević, Srđan and Vidojević, Katarina and Delić, Marija},
title = {Comparative Meta-Analysis of Survival, Risk, and Treatment Efficacy in Immunotherapy for Metastatic Melanoma Using Random-, Fixed-, and Mixed-Effects Models},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {14},
pages = {5017},
doi = {10.3390/jcm14145017}
}
EUVIMED